Intel's stock surged over 10% in a day, Hims & Hers skyrocketed 27%, and CVS finally made a comeback! In this week’s market recap, I break down key earnings, portfolio updates, and my 40% risk assessment for the coming week. Should you buy, hold, or sell these stocks? Let’s dive in!
🔹 Intel’s big move—can it sustain the rally?
🔹 Hims & Hers explodes after Super Bowl ad—overhyped or a buy?
🔹 CVS rebounds—strong earnings or just temporary momentum?
🔹 Portfolio updates: Why I sold Nvidia, Oracle, and Palo Alto Networks!
Don’t forget to like, comment, and subscribe for more in-depth stock market insights!
#StockMarketUpdate #Investing #IntelStock
💰 Weekly Market Recap & Portfolio Update (Feb 10 - Feb 14, 2025)
February brought volatility, breakouts, and key earnings that shook the market. I’ll go over the biggest stock moves, portfolio changes, and a risk assessment to help navigate the upcoming week.
Next weeks earnings
🔥 1. Intel (INTC) — Government Support Sparks 10% Surge!
📉 Ticker: INTC
💰 Current Price: ~$44.50
📈 Weekly Gain: +10.2%
Intel had a monster week, rallying over 10% in a single day, fueled by:
✅ US Government backing domestic semiconductor manufacturing
✅ Rumors of a joint venture with TSMC
✅ Intel’s turnaround efforts gaining traction
Despite the surge, Intel still faces massive competition from NVIDIA (NVDA) and AMD (AMD). I’m still holding my shares but watching carefully—this could be a short-term hype rally.
🚀 2. Hims & Hers (HIMS) — Super Bowl Ad Sends Stock Up 27%!
📉 Ticker: HIMS
💰 Current Price: ~$18.25
📈 Weekly Gain: +27%
Hims & Hers stock exploded this week, following a massive Super Bowl ad campaign that put them on the radar of new investors.
📌 Why the rally?
✅ Subscription-based revenue growth (steady recurring income)
✅ Massive marketing boost from the Super Bowl
✅ Analyst upgrades & bullish sentiment
⚠ BUT... is it overvalued?
While the stock is on fire, the RSI is flashing overbought signals, so I sold my position for a quick trade. If it pulls back, I might re-enter.
💊 3. CVS Health (CVS) — Finally a Breakout!
📉 Ticker: CVS
💰 Current Price: ~$73.40
📈 Weekly Gain: +5%
After two years of pain, CVS finally broke out, thanks to:
✔ Strong Q4 earnings & raised 2025 guidance
✔ Solid 4.2% revenue growth YoY
✔ Improving fundamentals & dividend stability (4% yield)
I’m long on CVS, and my entry at $60 is finally in the green. Still a great long-term buy for dividend investors.
📉 Portfolio Adjustments — What I Bought & Sold This Week
🔴 Sold Positions
Nvidia (NVDA) ❌ — Took a loss, expecting a pullback post-earnings
Oracle (ORCL) ❌ — Sold ahead of earnings uncertainty
Palo Alto Networks (PANW) ❌ — Overextended, locking in profits
Target (TGT) ❌ — Weak outlook, time to move on
🟢 Added to Positions
Procter & Gamble (PG) ✅ — Defensive play, now 6.48% of portfolio
Google (GOOGL) ✅ — Increased holdings to 5.06%
Novo Nordisk (NVO) ✅ — Strong growth story, now 3.94% of portfolio
Brookfield (BAM) ✅ — Waiting on earnings before adding more
🚀 New Positions
Tesla (TSLA) ✅ — Short-term trade, looking to exit on a rally
Realty Income (O) ✅ — 5.7% dividend, monthly payer, solid REIT
⚠ Market Risk Assessment — Should You Be Cautious?
📅 Key Economic Events Next Week:
Wednesday: Fed Meeting Minutes (FOMC)
Friday: Existing Home Sales Report
📉 S&P 500 RSI: 57 (Moderate risk)
📊 MACD: Buy signal triggered
🔄 Stock Buybacks Open: Positive for market stability
💡 Risk Level: 40% (Medium-Low) → The market remains range-bound, waiting for a catalyst.
🔥 Final Thoughts: Should You Buy Intel, CVS, or Hims & Hers?
📌 Intel (INTC) — HOLD (Watching for a pullback)
📌 Hims & Hers (HIMS) — SELL (Overbought, looking for re-entry)
📌 CVS Health (CVS) — BUY (Solid earnings & long-term value)
💬 What’s your market outlook? Drop a comment below!
🚀 Subscribe for weekly stock market insights! Stay safe and trade smart!
Share this post